Patient‐related factors independently impact overall survival in patients with myelodysplastic syndromes: an <scp>MDS</scp>‐<scp>CAN</scp> prospective study

Eitemau Tebyg

• Overall survival in lower <scp>IPSS</scp> risk <scp>MDS</scp> by receipt of iron chelation therapy, adjusting for patient‐related factors and measuring from time of first red blood cell transfusion dependence: an <scp>MDS</scp>‐<scp>CAN</scp> analysis
  gan: Heather A. Leitch, et al.
  Cyhoeddwyd: (2017)
• Myelodysplastic syndromes with ring sideroblasts ( <scp>MDS‐RS</scp> ) and <scp>MDS</scp> /myeloproliferative neoplasm with <scp>RS</scp> and thrombocytosis ( <scp>MDS/MPN‐RS‐T</scp> ) – “ <scp>2021</scp> update on diagnosis, risk‐stratification, and management”
  gan: Mrinal M. Patnaik, et al.
  Cyhoeddwyd: (2021)
• Impact of central nervous system (<scp>CNS</scp>) prophylaxis on the incidence and risk factors for <scp>CNS</scp> relapse in patients with diffuse large <scp>B</scp>‐cell lymphoma treated in the rituximab era: a single centre experience and review of the literature
  gan: Hany R. Guirguis, et al.
  Cyhoeddwyd: (2012)
• <scp>WT</scp>1 vaccination in <scp>AML</scp> and <scp>MDS</scp>: A pilot trial with synthetic analog peptides
  gan: Jason Brayer, et al.
  Cyhoeddwyd: (2015)
• Differences in <scp>MDS</scp>‐<scp>UPDRS</scp> Scores Based on Hoehn and Yahr Stage and Disease Duration
  gan: Matěj Škorvánek, et al.
  Cyhoeddwyd: (2017)